Panel Discussion: Balancing Novel Biomarkers for Multiple Cancer Types for DDR Inhibitor Development
Time: 12:00 pm
day: Pre-Conference Day
Details:
• Can we repurpose biomarkers used by other areas of oncology?
• What do we need to know to develop and validate biomarkers amongst the complexity of DDR pathways?
• Are novel target specific biomarkers for every novel target a worthwhile pursuit or realistic goal? Should we aim for a universal DDR biomarker?
